ATHA Similar Chart Price Prediction
The price of ATHA is predicted to go up 7.11%, based on the high correlation periods with HMN. The similarity of these two price pattern on the periods is 97.92%.
ATHA
HMN
Up: 7.11%Similarity: 97.92%
ATHA Revenue Forecast
ATHA EPS Forecast
ATHA Analyst's Forecast
Graig Suvannavejh
Mizuho
Buy → Hold
2024-09-19
Price Target
$5 → $0.5
Upside
+19.05%
Mizuho downgraded Athira Pharma to Neutral from Outperform with a price target of 50c, down from $5. The firm cites the negative Phase 2/3 LIFT-AD study data for the company's lead asset fosgonimeton in Alzheimer's disease and yesterday's announcement of a fosgonimeton program termination for the downgrade. The firm says the first top-line efficacy data for ATH-1105 in amyotrophic lateral sclerosis, likely coming in 2026, may provide an opportunity to revisit the thesis.
